![]() |
市场调查报告书
商品编码
1667210
空间基因组学和转录组学市场:按产品类型、样本类型、工作流程、应用、最终用户和地区进行的全球分析和预测(2024-2034 年)Spatial Genomics and Transcriptomics Market - A Global and Regional Analysis: Focus on Product Type, Sample Type, Workflow, Application, End User, and Region - Analysis and Forecast, 2024-2034 |
全球空间基因组学和转录组学市场规模预计将从 2023 年的 5.739 亿美元激增至 2034 年的 21.586 亿美元,预测期内的复合年增长率为 12.54%。
市场正在经历显着的增长,主要是由于空间体学在药物发现和营销中的应用越来越广泛、定序技术的进步、对高分辨率单细胞分析的需求不断增长以及癌症和神经系统疾病等复杂疾病的患病率不断上升。此外,随着研究人员和临床医生寻求在分子水平上更准确地了解疾病机制,空间基因组学在个人化医疗和精准肿瘤学中的日益广泛的应用预计将推动市场的发展。
主要市场统计数据 | |
---|---|
预测期 | 2024-2034 |
2024 年评估 | 6.623亿美元 |
2034 年预测 | 21.586亿美元 |
复合年增长率 | 12.54% |
由于政府和私人机构对基因组学研究的投资不断增加,以及生物技术公司和学术机构之间的合作,全球太空基因组学和转录组学市场正在经历显着增长,从而加速了空间分析技术的采用。随着对空间转录组学的投资不断增加,该领域将实现显着的成长和突破。持续的资金支持无疑将促进空间基因表现分析的进一步发展,增强其重塑研究范式和重新定义精准医疗边界的潜力。
按产品类型划分,套件和检测试剂占据主导地位:
根据产品类型,套件和检测部分预计将在 2023 年占据最大份额,预计到 2034 年将达到 11.162 亿美元,预测期内的复合年增长率为 12.27%。这项优势源自于它们在空间分析工作流程中的重要作用,为样本製备、染色和检测提供关键试剂和工具。这些产品的应用包括单细胞分析、组织分析和药物发现,在肿瘤学、免疫学、神经科学和其他研究领域至关重要。此外,随着许多研究机构和製药公司越来越多地转向外包服务以进行客製化分析、资料解释和生物标记发现,服务业也正在获得发展动力。如此强大的产品加上不断扩展的服务能力预计将在未来几年推动整个空间基因组学和转录组学市场的成长。
根据样本类型,新鲜冷冻组织部分占主导地位:
根据样本类型,新鲜冷冻组织部分预计将在 2023 年占据最大份额,预计到 2034 年将达到 11.318 亿美元,预测期内的复合年增长率为 12.40%。新鲜冷冻组织是采集后立即冷冻的生物组织,以保持其分子完整性。此领域的成长主要源自于临床研究和诊断应用对保存组织完整形态、蛋白质、DNA 和 RNA 的需求。新鲜冷冻组织保持其结构完整性并提供研究实验所必需的最佳通透条件。
根据工作流程,空间成像部分占主导地位:
根据工作流程,空间成像部分预计将在 2023 年占据最大份额,预计到 2034 年将达到 10.957 亿美元,预测期内的复合年增长率为 12.29%。空间成像可以探勘遗传物质(DNA)和基因[去除]RNA)在其原生组织环境中的空间组织。受成像技术、质谱流式细胞仪和质谱技术创新的推动,这一领域正在经历显着的成长。此外,人工智慧和机器学习(ML)的进步进一步提高了影像重建的准确性和效率,使得即时空间成像越来越逼真。透过利用大型资料集和自适应学习演算法,AI 和 ML 解决了现有的限制,并以更高的准确性和速度增强了影像处理和解释。
细分一:依产品类型
细分 2:依样本类型
细分 3:依工作流程
细分 4:按应用
细分 5:按最终用户
地理细分
本报告研究了全球空间基因组学和转录组学市场,并总结了主要趋势,分析了市场影响因素、法律制度、市场规模趋势和预测,并按各个细分市场、地区/主要国家进行了详细分析,介绍了竞争格局,并介绍了主要企业的概况。
范围和定义
Introduction of Spatial Genomics and Transcriptomics
The global spatial genomics and transcriptomics market, initially valued at $573.9 million in 2023, is set to witness substantial growth, projected to surge to $2,158.6 million by 2034, marking a remarkable compound annual growth rate (CAGR) of 12.54% over the period from 2024 to 2034. The market has been experiencing significant growth, primarily fuelled by the increasing use of spatial omics for drug discovery and development, advancements in sequencing technologies, increasing demand for high-resolution single-cell analysis, and the rising prevalence of complex diseases such as cancer and neurological disorders. Moreover, the increasing applications of spatial genomics in personalized medicine and precision oncology are expected to expand the market as researchers and clinicians seek more accurate insights into disease mechanisms at the molecular level.
Market Introduction
KEY MARKET STATISTICS | |
---|---|
Forecast Period | 2024 - 2034 |
2024 Evaluation | $662.3 Million |
2034 Forecast | $2,158.6 Million |
CAGR | 12.54% |
The global spatial genomics and transcriptomics market has been experiencing significant growth, fueled by growing investments in genomics research by government and private organizations and collaborations between biotech firms and academic institutions, and is accelerating the adoption of spatial analysis techniques. As investment in spatial transcriptomics continues to rise, the field is positioned for significant growth and transformative breakthroughs. The ongoing financial support will undoubtedly catalyze further advancements in spatial gene expression analysis, reinforcing its potential to reshape research paradigms and redefine the boundaries of precision medicine. For instance, in 2024, Moleculent AB secured $26 million in a Series A financing round led by ARCH Venture Partners and co-led by Eir Ventures. The company's innovative functional biology platform enables the detection and profiling of cell interactions directly within their native tissue environments. Therefore, such financial support supports technological innovations and expands spatial transcriptomics applications in various research domains.
Industrial Impact
The spatial genomics and transcriptomics market has significantly influenced the healthcare landscape, driven by key players such as 10x Genomics, Illumina, Inc., and Akoya Biosciences, Inc. These companies are at the forefront, providing cutting-edge platforms for spatially resolved genomic and transcriptomic profiling.
Moreover, the market has been further shaped by strategic collaborations, mergers, and R&D investments, which enable companies to expand their global presence and introduce innovative solutions. With the increasing focus on understanding tissue architecture and disease mechanisms, the competitive landscape of the spatial genomics and transcriptomics market is dynamic, with innovation and customer-centric approaches driving differentiation and growth.
Market Segmentation for Spatial Genomics and Transcriptomics Market:
Segmentation 1: by Product Type
Kits and Assays Segment to Dominate the Spatial Genomics and Transcriptomics Market (by Product Type)
Based on product type, the global spatial genomics and transcriptomics market was led by the kits and assays segment, which accounted for the largest share in 2023 and is expected to reach $1,116.2 million by 2034, registering a CAGR of 12.27% during the forecast period 2024-2034. This dominance can be attributed to their essential role in spatial analysis workflows, providing critical reagents and tools for sample preparation, staining, and detection. With applications spanning single-cell analysis, tissue profiling, and drug discovery, these products have become indispensable across research areas such as oncology, immunology, and neuroscience. Additionally, the services segment has gained traction, as many institutions and pharmaceutical companies increasingly rely on outsourcing services for customized analysis, data interpretation, and biomarker discovery. This combination of robust product offerings and expanding service capabilities is expected to propel the overall growth of the spatial genomics and transcriptomics market in the coming years.
Segmentation 2: by Sample Type
Fresh Frozen Tissues Segment to Dominate the Spatial Genomics and Transcriptomics Market (by Sample Type)
Based on sample type, the global spatial genomics and transcriptomics market was led by the fresh frozen tissues segment, which accounted for the largest share in 2023 and is expected to reach $1,131.8 million by 2034, registering a CAGR of 12.40% during the forecast period 2024-2034. Fresh frozen tissues are biological tissues that are frozen immediately after collection to preserve their molecular integrity. The segmental growth is primarily driven by the need to preserve tissue with intact morphology, proteins, DNA, and RNA for clinical research and diagnostic applications. Fresh frozen tissues maintain structural integrity and provide optimal permeabilization conditions, which are critical for research experiments. Leading companies such as 10x Genomics and Akoya Biosciences, Inc. offer advanced imaging technologies and solutions tailored for fresh frozen tissue types, further accelerating market expansion.
Segmentation 3: by Workflow
Spatial Imaging Segment to Dominate the Spatial Genomics and Transcriptomics Market (by Workflow)
Based on workflow, spatial imaging accounted for the largest share in 2023 and is expected to reach $1,095.7 million by 2034, registering a CAGR of 12.29% during the forecast period 2024-2034. Spatial imaging enables the exploration of the spatial organization of genetic material (DNA) and gene [removed]RNA) within their native tissue environment. The segment has experienced significant growth, driven by innovations in imaging technologies, mass cytometry, and mass spectrometry. Additionally, advancements in artificial intelligence (AI) and machine learning (ML) have further improved the accuracy and efficiency of image reconstruction, making real-time spatial imaging increasingly viable. By harnessing large datasets and adaptive learning algorithms, AI and ML address existing limitations, enhancing image processing and interpretation with greater precision and speed.
Segmentation 4: by Application
Drug Discovery and Development Segment to Dominate the Spatial Genomics and Transcriptomics Market (by Application)
Based on application, the drug discovery and development segment accounted for the largest share in 2023 and is expected to reach $688.4 million by 2034, registering a CAGR of 12.47% during the forecast period 2024-2034. The segment is majorly driven by the adoption of spatial technologies in identifying novel drug targets, understanding disease pathways, and optimizing preclinical studies through spatial insights into tissue microenvironments. Further, the growth of the market can be attributed to the high throughput techniques required for the discovery of therapeutic targets for drug development. Moreover, the advent of spatial biology, including gene expression microarray and high-throughput RNA-sequencing in clinical and drug research, has also furthered the market's growth.
Segmentation 5: by End User
Academic Institutes and Research Institutes Segment to Dominate the Spatial Genomics and Transcriptomics Market (by End User)
Based on end user, academic institutes and research institutes accounted for the largest share in 2023 and are expected to reach $925.4 million by 2034, registering a CAGR of 12.47% during the forecast period 2024-2034. Academic and research institutions are among the primary end users of the spatial genomics and transcriptomics market. Research organizations constitute integral facilities for companies as well as independent academic research facilities. In the research laboratories, potential biomarkers are identified, and drugs are developed while acquiring targets through spatial analysis. In addition to this, research organizations are also responsible for exploring new opportunities for advancing gene expression analysis and capabilities.
Segmentation :6 by Region
In the spatial genomics and transcriptomics market in 2023, the North America region dominated the global market, and it is expected to hold its dominance throughout the forecast period 2024-2034. This can be attributed to several key factors, including various technological innovations, drug discovery, and increasing research activities. In North America, several established spatial biology companies are focusing on expanding their portfolio in spatial genomics and transcriptomics instruments and kits. They are collaborating with service providers and pharmaceutical giants to co-market sequencing solutions with their complementary precision medicine solutions. Moreover, the availability of investors and venture capitalists capable of investing in the development of precision drugs and providing funds to start-ups in spatial biology has been furthering the market's growth.
Recent Developments in the Spatial Genomics and Transcriptomics Market
Demand - Drivers, Challenges, and Opportunities
Market Drivers:
Increasing Use of Spatial Omics for Drug Discovery and Development: The field of drug discovery and development is undergoing a transformative shift with the growing integration of spatial omics technologies, which are enabling a deeper and more accurate understanding of disease biology, therapeutic targets, and biomarkers of disease and therapeutic response. Traditional drug development heavily relied on bulk tissue samples, which often provided limited insights due to their inability to capture the heterogeneous nature of disease pathology. With the advent of spatial omics, including techniques such as digital spatial profiling (DSP), research scientists can now perform high-resolution, in situ analysis of RNA, DNA, and protein expression, offering unprecedented spatial context to the molecular landscape of disease tissues.
Market Challenges:
Lack of Skilled Professionals: A significant restraint in adopting and expanding spatial genomics and transcriptomics technologies is the lack of a skilled workforce. Clinical genomics laboratories, critical for implementing these advanced techniques, are already facing acute staff shortages, particularly in the U.S. As per an article titled ' Exploring current challenges in the technologist workforce of clinical genomics laboratories,' published in 2023, while medical technologists play a vital role in laboratory operations, the specialized nature of spatial genomics and transcriptomics demands expertise in both molecular biology and bioinformatics. This dual proficiency is not commonly available, further exacerbating workforce challenges.
Market Opportunities:
Integration of Artificial Intelligence in Spatial Genomics and Transcriptomics: The spatial genomics and transcriptomics market presents a significant opportunity driven by advancements in computational tools designed to enhance and impute spatial gene expression. These tools, leveraging cutting-edge artificial intelligence (AI) and deep learning technologies, are transforming data resolution and accuracy, addressing critical technical challenges in spatial transcriptomics (ST) analysis.
How can this report add value to an organization?
Product/Innovation Strategy: The global spatial genomics and transcriptomics market has been extensively segmented based on various categories, such as product type, sample type, workflow, application, end user, and region.
Growth/Marketing Strategy: Mergers, acquisitions, and product launches accounted for the maximum number of key developments.
Competitive Strategy: The global spatial genomics and transcriptomics market has numerous established players with product portfolios. Key players in the global spatial genomics and transcriptomics market analyzed and profiled in the study involve established players offering products for spatial genomics and transcriptomics.
Methodology
Key Considerations and Assumptions in Market Engineering and Validation
Primary Research:
The primary sources involve industry experts in spatial genomics and transcriptomics, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
The key data points taken from the primary sources include:
Secondary Research
Open Sources
The key data points taken from the secondary sources include:
Key Market Players and Competition Synopsis
The companies profiled have been selected based on inputs gathered from primary experts, who have analyzed company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
Scope and Definition